

## Correction: Regulation of tumor suppressor EAF2 polyubiquitination by ELL1 and SIAH2 in prostate cancer cells

Xinpei Yu<sup>1,5,8,9</sup>, Junkui Ai<sup>1</sup>, Liquan Cai<sup>1</sup>, Yifeng Jing<sup>1,6</sup>, Dan Wang<sup>1</sup>, Jun Dong<sup>1</sup>, Laura E. Pascal<sup>1</sup>, Jian Zhang<sup>7</sup>, Rongcheng Luo<sup>8</sup>, Zhou Wang<sup>1,2,3,4</sup>

<sup>1</sup>Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, USA

<sup>2</sup>Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, USA

<sup>3</sup>Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, USA

<sup>4</sup>University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, USA

<sup>5</sup>Department of Geriatrics, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, China

<sup>6</sup>Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

<sup>7</sup>Center for Translational Medicine, Guangxi Medical University, Nanning, Guangxi, China

<sup>8</sup>Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, Guangzhou, China



<sup>9</sup>Guangdong Provincial Key Laboratory of Geriatric Infection and Organ Function Support and Guangzhou Key Laboratory of Geriatric Infection and Organ Function Support, Guangzhou, China

**Published:** December 24, 2019

**Copyright:** Yu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**This article has been corrected:** Due to errors during image assembly, the RFP-ELL1 merged image in Figure 4B is incorrect. The proper Figure 4 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2016; 7:29245–29254. <https://doi.org/10.18632/oncotarget.8588>

**A****B**

**Figure 4: Mutant EAF2<sup>K39-81-85-111R</sup> binding and co-localization with ELL1.** (A) HEK 293 cells were transfected with myc-EAF2, myc-EAF2<sup>K39-81-85-111R</sup>, or empty myc expression vector together with GFP-ELL1 or empty GFP expression vector for 36 h. The cell lysates were prepared for co-immunoprecipitation using anti-GFP antibody. The precipitates and whole cell lysates (1% input) were analyzed by immunoblotting using anti-myc and anti-GFP antibodies. GAPDH in the whole cell lysates was probed as loading control. (B) C4-2 cells were transfected with GFP, GFP-EAF2, GFP-EAF2<sup>K39-81-85-111R</sup>, RFP, and RFP-ELL1 expression vector alone or in the indicated combinations for 48 h. Subcellular localization was imaged with confocal microscopy. Image enlargement: 100 $\times$ . Data shown are representative of three independent experiments.